2. Effects of Allicin on Cardiovascular Risk Factors
The treatment for CVD is mainly focused on controlling risk factors
[16][17][12,13] and commonly includes pharmacological approaches and changes in lifestyle
[18][19][14,15]. Until now, this type of intervention has been unsuccessful, because two or more drugs are required for optimal control of risk factors and usually have undesirable secondary effects. For this reason, the search for therapeutic options that contribute to preventing or delaying the progression of CVD continues.
CVD has a multifactorial origin, which makes its treatment difficult, thus the objective of the present study was to collect the available information on allicin and its beneficial effects on cardiovascular risk factors. In summary, data from experimental and clinical studies show that allicin decreases hypertension, inflammation, platelet aggregation, hyperglycemia, fibrosis, oxidative stress, and apoptosis and improves lipid profile, arrhythmias, and endothelial and cardiac function. For those reasons, and its low toxicity
[5][6][20][21][25,26,56,90] allicin may be a reliable option for the treatment of the different clinic manifestations of CVD and its risk factors.
Allicin is an oily liquid, bright yellow in color, unstable, and with a short half-life
[7][27]. However, due to its hydrophobic nature, it can be readily absorbed through cell membranes without inducing any damage to the phospholipid bilayer
[22][107]. In this context, it has been reported that allicin is able to cross the erythrocyte cell membrane
[15][35]. Possibly in this way, allicin can be distributed to various cell types, organs, and systems, including the CS to exert its beneficial effects. On a molecular level, the primary effect of allicin seems to be as an antioxidant and the multiple downstream effects described could be due to an indirect effect, since it can act as a bifunctional antioxidant. Due to its structure, allicin can act as a direct antioxidant by reacting directly with free radicals and ROS, acting as a substrate for glutathione synthesis, reacting with glutathione to produce S-Allyl-mercaptan glutathione, with L-cysteine to produce S-Allyl-mercaptan cysteine or other molecules that also can act as antioxidants
[23][24][108,109]. On the other hand, allicin as an indirect antioxidant modulates the expression of cytoprotective genes. It is known that allicin reacts rapidly with the free thiol or sulfhydryl groups of the proteins in the cell membrane or in the different cell compartments
[14][15][34,35]. It is likely that through this mechanism, allicin modifies proteins, second messengers, or transcription factors implicated in the regulation of gene expression. The regulation in the expression of antioxidant enzymes related to the Nrf2/Keap1 signaling pathway is possibly one of the well-known mechanisms through which allicin exerts antioxidant effects and has been considered an indirect mechanism
[25][26][27][28][93,94,110,111]. Furthermore, it is tempting to hypothesize that the anti-inflammatory mechanisms of allicin related to the NF-κB/IκB-dependent pathway could be associated with activation or inhibition via the modification of sulfhydryl groups. However, further studies are required to confirm or discard the presence of sulfhydryl groups derivatives by allicin as the responsible mechanism involved in the regulation of cytoprotective gene expression. The antihypertensive effects of allicin may be exerted through the improvement of endothelial function and the modulation of proteins and substances associated with vasoactive responses (eNOS, angiotensin II receptors type 1 and type 2 (AT1R and AT2R), ET-1, cGMP, angiotensin, NO, and H2S). Through in vitro assays, it was demonstrated that allicin decreased the vascular reactivity to angiotensin II, and AT1R overexpression in the heart
[26][94]. Another antihypertensive effect of allicin was demonstrated by its effects on the stimulation of the AT2R expression in renal tissue in CKD
[29][72]. Moreover, the antioxidant effects of allicin could contribute to increasing the half-life of the vasoactive metabolites such as NO, and therefore to the maintenance of the vasodilatory actions. Additionally, the cardioprotective effects of allicin have been evidenced in the prevention of apoptosis of ischemic areas, as well as the induction of angiogenesis, which could be useful for the treatment of myocardial infarction, one of the first death causes worldwide
[30][31][32][33][34][35][2,3,75,77,79,81]. The antiapoptotic and angiogenic activities of allicin may be useful to restore blood flow inducing recovery of injured areas and the effects on the modulation of expression and function of ion channels open the possibility of the use of allicin as an antiarrhythmic agent and pro-angiogenic.
A possible disadvantage of allicin is its poor stability and half-life. Thus, to improve the stability and half-life of allicin, a group of researchers conjugated allicin and captopril producing S-allylmercaptocaptopril (CPSSA). This compound was more stable and showed antihypertensive, lipid-lowering, and homocysteine-reducing effects, leading to the proposal of the use of this new conjugated molecule as a therapeutic option for the treatment of CVD
[36][37][112,113]. Another study using an allicin-fenofibrate combination reported synergistic effects on the regulation of blood lipids and the improvement of vascular endothelial function
[38][45]. For improving the stability and half-life of allicin, and for improving delivery and releasing, investigations have reported delivery systems including emulsion gels, nano emulsions, liposomes, microcapsules, and enteric-coated tablets
[6][39][40][41][26,70,114,115].
Regarding the dose or concentration of allicin needed to obtain cardioprotective effects, allicin has demonstrated beneficial effects at low doses such as 8 mg/kg/day in experimental models
[42][88]. The clinical studies have been carried out in patients with cardiovascular disease and healthy volunteers aged 20 years or older and the doses used a range from 10 to 48 mg/kg/day. No side effects, included bad smell, were reported in short-term or long-term studies
[5][6][20][21][43][25,26,44,56,90]. However, healthy volunteers reported abdominal discomfort and stomachache subsequent to the administration of 48 mg of allicin once a day during dinner for 1 week on an empty stomach
[44][63]. The intake of allicin from some garlic presentations has caused bad body odor and breath, possibly because quantities greater than one gram of garlic are necessary to obtain allicin in >0.6 mg
[6][26].
NTo our knowledge, no study has used allicin in pediatric or children’s populations. A report assessed garlic extract therapy at 300 mg, 3 times a day/8 weeks, and no significant effect was observed on CVD risk factors in pediatric patients (8–18 years) with familial hyperlipidemia
[45][116]. However, in adolescents, the garlic dry extract is recommended as a single dose (100–200 mg) once or twice a day, and the use in children under 12 years of age is not recommended
[11][31]. Further studies are needed and will provide information about the safety, care, efficacy, and recommendations for the use of allicin in sensitive populations such as infants and children. Therefore, controlled clinical studies and trials with younger and pediatric patients are recommended to provide information about side effects or further data to support the use of allicin as a pharmacological option for the treatment of risk factors, pathogenic mechanisms, and clinical manifestations of CVD.
Garlic is a spice that has been attributed to beneficial effects on CV risk factors even since ancient times
[10][30], but, so far, it is not used as a therapeutic option mainly because there are no standardized data on dosage, there are no specified garlic-derived compounds, or controlled studies on pharmacokinetics and pharmacodynamics, that allows replicating the beneficial effects. Recently, research has focused on studying the purified garlic compounds, showing important effects on various diseases
[46][47][117,118]. Garlic has several sulfur compounds and depending on the species, maturation, processing method, or presentation, the quantity of one type of compound or another predominates
[12][32]. In this context, allicin a garlic-derived compound has been isolated, purified or synthesized, quantified, characterized, and used in different dosages for the treatment of several cardiovascular diseases
[6][22][26,107]. Despite the possible disadvantage of its poor stability
[22][107] and half-life, the scientific literature provides convincing data that allicin alone or combined with anti-hypertensive
[36][37][48][49][36,41,112,113] or anti-dyslipidemia drugs
[38][45] may provide cardioprotective effects. In this sense, the use of delivery systems may be useful to increase absorption, bioavailability and efficacy, thus the biological activities and health benefits
[6][26]. Allicin has shown beneficial effects on several metabolic alterations, risk factors, and cell injury. These effects have been observed in various organs, systems, and cell types (i.e., heart, endothelium, liver, and kidney). Therefore, this work provides a landscape of the scientific literature focusing on the beneficial effects of allicin on risk factors of CVD, as well as the cellular and molecular mechanisms involved.